• Researcher Profile

    Stuart H. Orkin, MD

     
    Stuart H. Orkin, MD

     
    Chair, Pediatric Oncology
    Associate Chief, Division of Hematology/Oncology, Boston Children's Hospital


    David G. Nathan Professor of Pediatrics, Harvard Medical School

    Center/Program

    Pediatric Hematologic Malignancies

    Office phone: 617-355-7910
    Fax: 617-632-4367
    Email: stuart_orkin@dfci.harvard.edu

    Preferred contact method: office phone

    View Physician Profile
     
     

    Research Department

    Pediatric Oncology

    Interest

    Pediatric hematology/oncology

    Area of Research

    Molecular Genetics of Blood Cell Development and Stem Cells

    Dana-Farber Cancer Institute
    450 Brookline Avenue
    Dana 1642
    Boston, MA 02215

    Biography

    Dr. Orkin received his MD in 1972 from Harvard Medical School, followed by postdoctoral research at the National Institutes of Health and clinical training in pediatrics and hematology-oncology at Children's Hospital Boston and DFCI, where he joined the faculty in 1978. Dr. Orkin is a Howard Hughes Medical Institute Investigator. Over the past decade, his laboratory has defined critical nuclear regulators of hematopoiesis.

    Recent Awards

    • AAMC Award for Distinguished Research in Medical Sciences, 2005
    • Warren Alpert Foundation Prize, 1993
    • Member, American Academy of Arts and Sciences, 1992
    • Member, Institute of Medicine, 1992
    • Member, National Academy of Sciences, 1991
    • Dameshek Award, American Society of Hematology, 1986

    Research

    Molecular Genetics of Blood Cell Development and Stem Cells

    All blood cells arise from committed progenitors, which are descendants of pluripotent hematopoietic stem cells. The goal of our laboratory is to understand how commitment to specific blood lineages is programmed and how cell-specific patterns of gene expression are established. Since gene expression is controlled by nuclear regulatory factors (transcription factors), efforts have centered on identifying those crucial for the development of stem cells or individual lineages. Research encompasses conventional molecular biology and contemporary mouse genetics.

    Lineage specification and hematopoietic differentiation
    Red blood cells and megakaryocytes (which produce platelets) share a common precursor cell. We discovered a transcription factor, GATA1, that participates in the regulation of virtually all red cell (erythroid) and megakaryocyte-specific expressed genes. Expression of GATA1 in progenitors drives cells toward erythroid and megakaryocytic fates. Disruption of the Gata1 gene in mice leads to a failure of maturation of both lineages. In addition to controlling end-stage markers of these lineages, GATA1 influences proliferation and cell death decisions of precursor cells. Using this mouse model to dissect mechanisms of cell differentiation, we have sought to understand how GATA1 functions in transcription. This line of investigation led us to hypothesize and then discover a cofactor required for GATA1's function in these lineages. This novel cofactor, FOG (for friend of GATA1), is also essential for normal red blood cell and megakaryocyte development. Current research focuses on how FOG modulates the function of GATA1 and related factors during hematopoietic and nonhematopoietic cell development.

    Hematopoiesis-leukemia interface
    Remarkably, many genes essential for normal hematopoietic development are involved in chromosomal translocations in human leukemias. This finding reflects perturbation of normal homeostasis by expression of an altered protein or excessive production of an otherwise normal factor. We are studying several transcription factors (e.g., SCL/tal-1, TEL) affected by genetic events in leukemias. Our work is directed toward understanding the normal roles of these transcription factors in hematopoiesis and vascular development. In addition, efforts are ongoing to recreate in mice the common form of childhood leukemia, acute lymphoblastic leukemia, associated with fusion of the TEL and AML1 genes. This animal model will permit improved understanding of the pathogenesis of acute lymphoblastic leukemia and provide a system for testing new therapies.

    Select Publications

    • Hock H, Hamblen MJ, Rooke HM, Schlinder JW, Saleque S, fujiwara Y, Orkin SH. Gfi-1 restricts proliferation and preserves functional integrity of haematopoietic stem cells. Nature 2004;431:1002-7.
    • Gekas C, Dieterlen-Lievre F, Orkin SH, Mikkola HK. The placenta is a niche for hematopoietic stem cells. Dev Cell 2005;8:365-75.
    • Li Z, Godinho FJ, Klusmann JH, Garriga-Canut M, Yu CA, Orkin SH. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet 2005;37:613-7.

    Trainees

    • Levasseur, Dana, PhD
    • Hartner, Jochen, PhD
    • Walkley, Carl, PhD
    • Shen, Xioaha, PhD
View Physician Directory

Find a Clinical Trial

Support Cancer
Research

Give Now